GCP
PHIO icon

GSA Capital Partners’s Phio Pharmaceuticals PHIO Stock Holding History

GSA Capital Partners’s Portfolio PHIO Stock Details PHIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$24K Buy
+19,864
New +$22.7K ﹤0.01% 1639
2021
Q2 		– Sell
-1,225
Closed -$355K – 1534
2021
Q1 		$355K Buy
1,225
+286
+30% +$95.1K 0.06% 549
2020
Q4 		$273K Buy
939
+742
+377% +$188K 0.04% 797
2020
Q3 		$46K Buy
+197
New +$50.1K 0.01% 1189

Other funds holding PHIO

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Cetera Investment Advisers
Cetera Investment Advisers Schaumburg, Illinois $94B AUM 20.14% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
SRL
Scientech Research LLC Jersey City, New Jersey $120M AUM 73.62% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return

GSA Capital Partners's PHIO Position: Q1 2026 in Review

GSA Capital Partners opened a new position in Phio Pharmaceuticals (PHIO) in Q1 2026: 19,864 shares worth $24K. The stake represents ﹤0.01% of the portfolio and ranks #1639 among its holdings. This is a return to the name: GSA Capital Partners previously reported a position in PHIO as recently as Q1 2021.

GSA Capital Partners first reported a position in PHIO in Q3 2020 and has held it in 4 quarters since. The position peaked at $355K in Q1 2021. 24 funds tracked by Wall St. Rank hold PHIO as of Q1 2026.

  • GSA Capital Partners held 19,864 shares of Phio Pharmaceuticals worth $24K as of Q1 2026.
  • Phio Pharmaceuticals was a new GSA Capital Partners position in Q1 2026.
  • Phio Pharmaceuticals made up ﹤0.01% of GSA Capital Partners's portfolio in Q1 2026, its #1639 holding.
  • GSA Capital Partners first reported a position in Phio Pharmaceuticals in Q3 2020 and has held it in 4 quarters since.
  • GSA Capital Partners's Phio Pharmaceuticals position peaked at $355K in Q1 2021.
  • 24 funds tracked by Wall St. Rank held Phio Pharmaceuticals as of Q1 2026.

Based on GSA Capital Partners's 13F filing for Q1 2026, filed 8 May 2026.